


## Table of Contents

	<u>Page</u>
1. INTRODUCTION .....	1
2. BACKGROUND OF THE INVENTION .....	1
3. SUMMARY OF THE INVENTION .....	2
4. DESCRIPTION OF THE FIGURES .....	3
5. DETAILED DESCRIPTION OF THE INVENTION .....	5
5.1 IDENTIFICATION OF HOST CELL PROTEINS THAT INTERACT WITH VIRAL PROTEINS REQUIRED FOR REPLICATION .....	7
5.2 SCREENING ASSAYS FOR COMPOUNDS THAT INTERFERE WITH THE INTERACTION OF HOST CELL AND VIRAL PROTEINS REQUIRED FOR VIRAL REPLICATION .....	12
5.2.1 ASSAY COMPONENTS .....	13
5.2.2 ASSAY FORMATS .....	16
5.3 ASSAYS FOR ANTIVIRAL ACTIVITY .....	18
5.3.1 VIRAL GROWTH ASSAYS .....	18
5.3.2 ANIMAL MODEL ASSAYS .....	19
5.4 INHIBITORY COMPOUNDS .....	19
5.5 PHARMACEUTICAL PREPARATIONS AND METHODS OF ADMINISTRATION .....	20
6. EXAMPLE: THE IDENTIFICATION OF NPI-1 AND ITS INTERACTION WITH INFLUENZA NUCLEOPROTEIN .....	22
6.1 MATERIALS AND METHODS .....	23
6.1.1 YEAST, BACTERIA AND PLASMIDS .....	23
6.1.2 SELECTION OF NP INTERACTORS .....	23
6.1.3 CLONING OF THE 5' TERMINUS OF NPI-1 .....	24
6.1.4 BACTERIAL EXPRESSION AND PURIFICATION OF GST-NPI-1 .....	24
6.1.5 NP BINDING ASSAY .....	25
6.1.6 ANTISERA AND IMMUNOBLOTTING .....	25
6.1.7 VIRUSES AND CELLS .....	25
6.2 RESULTS .....	26
6.2.1 ISOLATION OF NPI-1 .....	26
6.2.2 CLONING AND SEQUENCING OF THE NPI-1 cDNA .....	27
6.2.3 NPI-1 BINDS TO NP IN VITRO .....	28
6.2.4 IMMUNODETECTION OF NPI-1 IN CELL EXTRACTS .....	28
6.2.5 NPI-1 INTERACTS WITH NP IN INFECTED CELLS .....	28
7. EXAMPLE: THE IDENTIFICATION OF NS11-1 AND ITS INTERACTION WITH INFLUENZA NUCLEOPROTEIN NS1 .....	29
7.1 MATERIALS AND METHODS .....	29
7.1.1 YEAST, <i>E. COLI</i> STRAINS, AND PLASMIDS .....	29
7.1.2 IDENTIFICATION OF NS1-INTERACTORS .....	30
7.1.3 CLONING OF NS11-1 5'-END CDNA .....	30
7.1.4 NORTHERN BLOT ANALYSIS .....	31
7.1.5 VIRUSES, CELLS, AND EXTRACTS .....	31

Table of Contents  
(continued)

	<u>Page</u>
7.1.6 EXPRESSION OF GST-NS11-1 FUSION PROTEIN IN <i>E. COLI</i> AND PRECIPITATION OF VIRAL PROTEINS FROM CELL EXTRACTS .....	31
7.2 RESULTS .....	32
7.2.1 ISOLATION OF NS1-INTERACTING FACTORS.....	32
7.2.2 CLONING AND SEQUENCE ANALYSIS OF NS11-1 .....	33
7.2.3 NS11-1 BINDS NS1 PROTEIN FROM EXTRACTS OF INFLUENZA VIRUS INFECTED CELLS.....	34



## Notice to Comply

Application No.  
10/724,273

Applicant(s)  
Palese, P., et al.

Examiner  
Jeffrey S. Parkin

Art Unit  
1648

Paper No.  
05/29/2007

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Applicants are reminded that sequences appearing in the specification and/or drawings must be identified by a sequence identifier (SEQ ID NO.:) in accordance with 37 C.F.R. 1.821(d). Sequence identifiers for sequences appearing in the drawings may appear in the Brief Description of the Drawings. Applicant must provide appropriate amendments to the specification and/or drawings inserting the required sequence identifiers. Extensive amendments may necessitate the submission of a substitute specification and drawings.

#### Applicant May Need to Provide:

- ☒ An substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
  - For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
  - Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov).
- To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>.

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**